Table 1.
Clinical characteristics of patients treated with nivolumab.
| Variables | Patients (n = 62) n (%) |
|---|---|
| Age, years | |
| Median (range) | 63 (39–87) |
| Sex | |
| Men | 40 (64.5) |
| Women | 22 (35.5) |
| ECOG performance status | |
| 0 | 9 (14.5) |
| 1 | 43 (69.4) |
| 2 | 10 (16.1) |
| Smoking | |
| Never/light smoker | 23 (37.1) |
| Smoker | 39 (62.9) |
| Histology | |
| Adenocarcinoma | 47 (75.8) |
| Squamous cell carcinoma | 15 (24.2) |
| Mutation type | |
| EGFR mutation | 7 (11.3) |
| ALK or ROS1 rearrangement | 1 (1.6) |
| Wild type | 54 (87.1) |
| Previous treatment | |
| Chemotherapy | 35 (56.4) |
| Targeted therapy | 9 (14.5) |
| Immunotherapy | 0 (0) |
| Surgery | 4 (6.4) |
| Radiotherapy | 7 (11.2) |
| No. of prior therapies | |
| 1 | 29 (46.8) |
| 2 | 12 (19.4) |
| >2 | 21 (33.8) |